A Post-Market, Retrospective Study on 3D Metal Tibial and Femoral Cones
Launched by MEDACTA INTERNATIONAL SA · Aug 28, 2024
Trial Information
Current as of November 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a special type of knee replacement called the GMK Revision Knee System, which is designed for patients who need a second surgery after a previous knee replacement has failed or when there is significant bone loss. The trial focuses on using advanced 3D metal cones that provide extra support to the knee joint, helping to improve stability and function. It aims to gather information about how well these components work for patients who have had various types of knee problems, including arthritis and previous surgery failures.
To be eligible for this study, participants must have undergone a revision total knee replacement using the GMK Revision system and must be at least one year post-surgery. There are some exclusions, such as individuals with certain health conditions that could affect the study results. If you qualify, you can expect to share your experiences after your knee surgery, which will help researchers understand the effectiveness of this new technology in supporting people with knee issues.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects underwent revision total knee replacement for any type of etiology (Osteoarthritis, Avascular necrosis, Rheumatoid Arthritis, Post-traumatic Arthritis, Polyarthritis, Primary implantation failure, Infection, Ligamentous Instability)
- • Subjects must have received a Medacta GMK Revision component using 3D metal tibial and femoral cones
- • Must be at minimum 1 year (12 months) post-treatment
- • No age limit criteria
- Exclusion Criteria:
- • Subjects with neuromuscular or neurosensory deficiency, which would limit the ability to assess the performance of the device
- • Subjects that were incarcerated at the time of surgery.
- • History of alcoholism
- • On chemotherapy or radiation therapy during the time of interest
- • Habitual use of narcotic pain medications prior to surgery or after surgery for reasons other than knee pain
- • History of a metabolic disorder affecting the skeletal system other than osteoarthritis or osteoporosis
- • History of chronic pain issues for reasons other than knee pain
- • Progressive local or systemic infection during time of interest
- • Muscular loss, neuromuscular disease, or vascular deficiency of the affected limb
- • Obesity or excessive weight of subject
About Medacta International Sa
Medacta International SA is a leading global medical device company specializing in innovative orthopedic solutions, particularly in the fields of joint replacement and minimally invasive surgery. Founded in 1999 and headquartered in Switzerland, Medacta is committed to advancing patient care through cutting-edge technologies and comprehensive educational programs for healthcare professionals. The company’s robust portfolio includes proprietary implants and instrumentation designed to enhance surgical outcomes and improve patient quality of life. With a strong emphasis on research and development, Medacta actively engages in clinical trials to validate the efficacy and safety of its products, positioning itself as a trusted partner in the orthopedic community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported